Nuvo, partner win FDA approval

The FDA has approved a new osteoarthritis therapy developed by Covidien and Nuvo Research. The non-steroidal anti-inflammatory Pennsaid will be marketed for osteoarthritis symptoms in the knee. Nuvo owns the IP on the product and Covidien will handle commercialization in the U.S. They're looking to launch in the first half of the year. Story

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.